JLABS, Tuesday Morning, March 28, 2017
Topic: “Meet with …MPM Capital”
Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;
Luke Evnin | Managing Director, MPM Capital
Date and Time: Tuesday, March 28, 2017, 10:30 am
10:30am | Registration & Networking
11:00am | Presentation and Q&A
11:45am | Lunch & Networking
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Registration at https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?a...
Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a $400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a $470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). For more information on MPM visit http://www.mpmcapital.com/
Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evnin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.
Luke Evnin, Ph.D., co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novatris: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.
Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Insitiute for Quantitative Gernomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.
Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team.
Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.